We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
+7.15%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$2.94B
AUM Growth
-$464M
Cap. Flow
-$553M
Cap. Flow %
-18.83%
Top 10 Hldgs %
35.63%
Holding
94
New
11
Increased
10
Reduced
24
Closed
23

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$66.6M
2
JNJ icon
Johnson & Johnson
JNJ
+$53.2M
3
IRTC icon
iRhythm Holdings
IRTC
+$48.1M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$38.4M
5
CAH icon
Cardinal Health
CAH
+$31.4M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$57.5M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$51.2M
3
HCA icon
HCA Healthcare
HCA
+$47.7M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$43.2M
5
GILD icon
Gilead Sciences
GILD
+$40.6M

Sector Composition

Rank Sector Weight
1 Healthcare 94.07%
2 Financials 0.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCUS icon
1
Arcus Biosciences
RCUS
$3.77B
$139M 4.73%
3,431,010
– –
OM icon
2
Outset Medical
OM
$76.6M
$136M 4.61%
196,017
-1,764
-0.9% -$1.3M
ABBV icon
3
AbbVie
ABBV
$448B
$124M 4.23%
916,496
– –
HZNP
4
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$118M 4.01%
1,091,840
-469,450
-30% -$51.2M
CYTK icon
5
Cytokinetics
CYTK
$11.2B
$112M 3.83%
2,465,016
-694,685
-22% -$26.8M
CNC icon
6
Centene
CNC
$32.5B
$91.7M 3.12%
1,112,480
+127,609
+13% +$9.35M
AVTR icon
7
Avantor
AVTR
$7.48B
$87.6M 2.98%
2,079,657
– –
LLY icon
8
Eli Lilly
LLY
$1.04T
$82.5M 2.81%
298,643
-226,812
-43% -$57.5M
PFE icon
9
Pfizer
PFE
$141B
$79.3M 2.7%
+1,343,384
New +$66.6M
ERAS icon
10
Erasca
ERAS
$6.77B
$77M 2.62%
5,191,405
– –
IQV icon
11
IQVIA
IQV
$33.1B
$67.2M 2.29%
238,039
-119,877
-33% -$31.1M
HUM icon
12
Humana
HUM
$47.7B
$64.7M 2.2%
139,420
– –
IRTC icon
13
iRhythm Holdings
IRTC
$3.49B
$61.7M 2.1%
+523,982
New +$48.1M
UHS icon
14
Universal Health Services
UHS
$9.04B
$61.6M 2.1%
475,340
-45,446
-9% -$5.84M
CRBU icon
15
Caribou Biosciences
CRBU
$165M
$59.4M 2.02%
4,092,309
– –
DHR icon
16
Danaher
DHR
$126B
$57.8M 1.97%
198,178
– –
UNH icon
17
UnitedHealth
UNH
$392B
$56M 1.91%
111,554
-33,741
-23% -$15.3M
MYGN icon
18
Myriad Genetics
MYGN
$535M
$55.9M 1.9%
2,025,681
-847,237
-29% -$24.5M
JNJ icon
19
Johnson & Johnson
JNJ
$615B
$55.6M 1.89%
+324,972
New +$53.2M
DVAX
20
DELISTED
Dynavax Technologies
DVAX
$53.5M 1.82%
3,805,370
+521,800
+16% +$8.59M
ICUI icon
21
ICU Medical
ICUI
$3.93B
$52.4M 1.78%
220,587
– –
PEN icon
22
Penumbra
PEN
$12.4B
$50.9M 1.73%
177,088
– –
HCA icon
23
HCA Healthcare
HCA
$82.5B
$50.3M 1.71%
195,621
-194,886
-50% -$47.7M
ICLR icon
24
Icon
ICLR
$12.9B
$49M 1.67%
158,183
– –
EW icon
25
Edwards Lifesciences
EW
$48.6B
$48.4M 1.65%
373,492
-139,513
-27% -$16.3M
1
2 3 4

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
CPRC
Consolidated Portfolio Review Corp Woodbury, New York $1.1B AUM 8.96% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
PRS
Pinkerton Retirement Specialists Coeur D Alene, Idaho $1.1B AUM 30.57% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
CF
Corebridge Financial Houston, Texas $1.09B AUM 1.85% 1-Year Est. Return

PFM Health Sciences's Q4 2021 Portfolio in Review

As of Q4 2021, PFM Health Sciences held 94 positions worth $2.94B, down 14% from $3.4B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

PFM Health Sciences withdrew a net $553M in Q4 2021, closing 23 positions and reducing 24 holdings. Its most notable exit was Allogene Therapeutics, an estimated $19.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 86% a quarter earlier, followed by Financials.

Against the trend, PFM Health Sciences opened a new position in Pfizer worth $79.3M.

  • PFM Health Sciences's largest Q4 2021 buy was Pfizer: 1,343,384 shares worth $79.3M.
  • PFM Health Sciences added most to CATALENT, INC. in Q4 2021, an estimated $19.1M increase.
  • PFM Health Sciences's biggest Q4 2021 reduction was Eli Lilly, cutting an estimated $57.5M.
  • PFM Health Sciences fully exited Allogene Therapeutics in Q4 2021, selling an estimated $19.9M.
  • PFM Health Sciences's ten largest holdings make up 36% of its $2.94B portfolio in Q4 2021.
  • PFM Health Sciences opened 11 new positions and closed 23 in Q4 2021.
  • PFM Health Sciences's portfolio value fell 14% quarter-over-quarter to $2.94B.

Based on PFM Health Sciences's 13F filing for Q4 2021, filed 14 Feb 2022.